Study Evaluating Pharmacovigilance Of Refacto AF

Pfizer

Status: Completed

Conditions: Hemophilia A

Treatments: Drug: ReFacto AF (Moroctocog alfa)

Study type: Observational

Funder types: Industry

Identifiers

NCT00895037

3082B2-4420

B1831016 (Other Identifier)

Details and patient eligibility

About

The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.

Full description

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Enrollment: 101 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hemophilia A of any severity already receiving or starting treatment with ReFacto AF.

Exclusion criteria

• Patients with Hemophilia A treated with a product other than Refacto AF.

Trial design

101 participants in 1 patient group

1

Description:

Patients treated with Refacto AF

Treatment:

Drug: ReFacto AF (Moroctocog alfa)